Market Overview

UPDATE: Benchmark Raises PT to $20 on Exact Sciences Corporation Ahead of Top Line Data

Share:
Related EXAS
Goldman Sachs Cuts Myriad Genetics To Sell, Ups Alere
Exact Sciences Grants Inducement Restricted Stock Unit Awards to New Employees

Benchmark maintained Exact Sciences Corporation (NASDAQ: EXAS) with a Speculative Buy and raised the price target from $17.00 to $20.00.

Benchmnark noted, "Exact's Q4 update affirmed our expectation that pivotal top line colorectal cancer study data should be announced in March or April. These results are expected to support the third and final modular PMA filing seeking approval of a colon cancer and pre-cancer screening test. Based on prior tests demonstrating up to 98% cancer sensitivity, we believe there is a high likelihood this prospective study can demonstrate cancer sensitivity that exceeds the FDA's anticipated 85% threshold for approval."

Exact Sciences Corporation closed at $10.56 on Wednesday.

Latest Ratings for EXAS

DateFirmActionFromTo
Mar 2015Goldman SachsDowngradesBuyNeutral
Feb 2015JMP SecuritiesMaintainsMarket Outperform
Jan 2015Lake Street CapitalInitiates Coverage onBuy

View More Analyst Ratings for EXAS
View the Latest Analyst Ratings

Posted-In: BenchmarkAnalyst Color Price Target Analyst Ratings

 

Related Articles (EXAS)

Around the Web, We're Loving...